Prognostic impact of CD133 expression in Endometrial Cancer Patients

Abstract To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. Mancebo, J. M. Sole-Sedeno, O. Pino, E. Miralpeix, S. Mojal, L. Garrigos, B. Lloveras, P. Navarro, J. Gibert, M. Lorenzo, I. Aran, R. Carreras, F. Alameda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3ddb17437f2a4cff903814dfb8c2706d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ddb17437f2a4cff903814dfb8c2706d
record_format	dspace
spelling	oai:doaj.org-article:3ddb17437f2a4cff903814dfb8c2706d2021-12-02T12:32:50ZPrognostic impact of CD133 expression in Endometrial Cancer Patients10.1038/s41598-017-08048-02045-2322https://doaj.org/article/3ddb17437f2a4cff903814dfb8c2706d2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08048-0https://doaj.org/toc/2045-2322Abstract To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154–168) as compared with 146 months (95% CI, 123–160) for those with CD133- tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149–168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251–17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.G. ManceboJ. M. Sole-SedenoO. PinoE. MiralpeixS. MojalL. GarrigosB. LloverasP. NavarroJ. GibertM. LorenzoI. AranR. CarrerasF. AlamedaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q G. Mancebo J. M. Sole-Sedeno O. Pino E. Miralpeix S. Mojal L. Garrigos B. Lloveras P. Navarro J. Gibert M. Lorenzo I. Aran R. Carreras F. Alameda Prognostic impact of CD133 expression in Endometrial Cancer Patients
description	Abstract To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154–168) as compared with 146 months (95% CI, 123–160) for those with CD133- tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149–168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251–17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.
format	article
author	G. Mancebo J. M. Sole-Sedeno O. Pino E. Miralpeix S. Mojal L. Garrigos B. Lloveras P. Navarro J. Gibert M. Lorenzo I. Aran R. Carreras F. Alameda
author_facet	G. Mancebo J. M. Sole-Sedeno O. Pino E. Miralpeix S. Mojal L. Garrigos B. Lloveras P. Navarro J. Gibert M. Lorenzo I. Aran R. Carreras F. Alameda
author_sort	G. Mancebo
title	Prognostic impact of CD133 expression in Endometrial Cancer Patients
title_short	Prognostic impact of CD133 expression in Endometrial Cancer Patients
title_full	Prognostic impact of CD133 expression in Endometrial Cancer Patients
title_fullStr	Prognostic impact of CD133 expression in Endometrial Cancer Patients
title_full_unstemmed	Prognostic impact of CD133 expression in Endometrial Cancer Patients
title_sort	prognostic impact of cd133 expression in endometrial cancer patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/3ddb17437f2a4cff903814dfb8c2706d
work_keys_str_mv	AT gmancebo prognosticimpactofcd133expressioninendometrialcancerpatients AT jmsolesedeno prognosticimpactofcd133expressioninendometrialcancerpatients AT opino prognosticimpactofcd133expressioninendometrialcancerpatients AT emiralpeix prognosticimpactofcd133expressioninendometrialcancerpatients AT smojal prognosticimpactofcd133expressioninendometrialcancerpatients AT lgarrigos prognosticimpactofcd133expressioninendometrialcancerpatients AT blloveras prognosticimpactofcd133expressioninendometrialcancerpatients AT pnavarro prognosticimpactofcd133expressioninendometrialcancerpatients AT jgibert prognosticimpactofcd133expressioninendometrialcancerpatients AT mlorenzo prognosticimpactofcd133expressioninendometrialcancerpatients AT iaran prognosticimpactofcd133expressioninendometrialcancerpatients AT rcarreras prognosticimpactofcd133expressioninendometrialcancerpatients AT falameda prognosticimpactofcd133expressioninendometrialcancerpatients
_version_	1718393912046911488

Prognostic impact of CD133 expression in Endometrial Cancer Patients

Ejemplares similares